These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 23916468)
1. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468 [TBL] [Abstract][Full Text] [Related]
2. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Xie M; He CS; Wei SH; Zhang L Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913 [TBL] [Abstract][Full Text] [Related]
3. Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer. Ju L; Zhou C Cancer Biomark; 2013; 13(5):329-36. PubMed ID: 24440972 [TBL] [Abstract][Full Text] [Related]
4. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409 [TBL] [Abstract][Full Text] [Related]
5. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Cufí S; Bonavia R; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Joven J; Bosch-Barrera J; Micol V; Menendez JA Sci Rep; 2013; 3():2459. PubMed ID: 23963283 [TBL] [Abstract][Full Text] [Related]
6. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169 [TBL] [Abstract][Full Text] [Related]
8. Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lara-Guerra H; Chung CT; Schwock J; Pintilie M; Hwang DM; Leighl NB; Waddell TK; Tsao MS Lung Cancer; 2012 May; 76(2):235-41. PubMed ID: 22112291 [TBL] [Abstract][Full Text] [Related]
9. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Segura-Carretero A; Joven J; Martin-Castillo B; Barrajón-Catalán E; Micol V; Bosch-Barrera J; Menendez JA Cell Cycle; 2013 Nov; 12(21):3390-404. PubMed ID: 24047698 [TBL] [Abstract][Full Text] [Related]
10. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905 [TBL] [Abstract][Full Text] [Related]
11. Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT. Li D; Zhang L; Zhou J; Chen H Lung Cancer; 2016 Mar; 93():35-42. PubMed ID: 26898612 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170 [TBL] [Abstract][Full Text] [Related]
13. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Rho JK; Choi YJ; Jeon BS; Choi SJ; Cheon GJ; Woo SK; Kim HR; Kim CH; Choi CM; Lee JC Mol Cancer Ther; 2010 Dec; 9(12):3233-43. PubMed ID: 21159609 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
15. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of silibinin on tumour necrosis factor-alpha and hydrogen peroxide production by human monocytes. Bannwart CF; Peraçoli JC; Nakaira-Takahagi E; Peraçoli MT Nat Prod Res; 2010 Nov; 24(18):1747-57. PubMed ID: 20981616 [TBL] [Abstract][Full Text] [Related]
17. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894 [TBL] [Abstract][Full Text] [Related]
18. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648 [TBL] [Abstract][Full Text] [Related]
19. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]